Invitrogen Introduces NCode™ MicroRNA Microarray Platform
Product News Nov 15, 2005
Invitrogen Corporation has announced that it has introduced its NCode™ microRNA Microarray platform.
Invitrogen claims that, the NCode™ miRNA profiling platform enables sensitive profiling of miRNAs while using extremely simple methods that provide both experienced and novice microarray users a rapid path to discoveries.
NCode™ permits researchers to study miRNA function by allowing researchers to profile the miRNA expression patterns in a given disease or developmental state.
Research has suggested that miRNAs regulate up to 30 percent of human genes, including those linked with cancer, infectious disease, and development.
Because of their different physical traits, miRNAs require modified sample preparation and profiling methods from previous DNA microarray experiments.
The NCode™ Multi-Species miRNA Array Platform enables researchers to profile all known miRNAs from humans, plus additional human predicted miRNAs, mouse, rat, Drosophila, c.elegans, and zebrafish.
"miRNAs appear to play diverse roles in critical processes like oncogenesis, stem cell differentiation, and host-pathogen interactions," said Peter Welch, Ph.D., R&D Director for Gene Regulation at Invitrogen.
"The promise of discovering superior predictors of disease and developing treatments for currently non-druggable targets has certainly captured the interest of academia and the pharmaceutical industry."
"We hope to accelerate research findings in these areas by providing an integrated solution that delivers the sensitivity, specificity, and coverage that the research community needs."
"We've found distinct patterns of miRNA expression in differentiating neural stem cells, consistent with a regulatory role for miRNAs in both neurogenesis and gliogenesis," explained Ron Hart, Ph.D., Professor of Cell Biology and Neuroscience at the W.M. Keck Center for Collaborative Neuroscience at Rutgers University.
"Having the ability to use sensitive microarrays to survey full sets of miRNAs in neural stem cells during differentiation both in culture and in vivo allowed us to detect novel patterns of regulated miRNAs systematically."
"Several individual miRNAs have already proven requisite for differentiation of specific cell types," Dr. Hart added.
"Understanding these unexpected regulatory mechanisms provides novel targets for potentially managing or controlling differentiation in stem cells prior to therapeutic transplant."
The NCode™ miRNA Microarray Platform will be available in December 2005.